|
Name |
Neopestalotin A
|
| Molecular Formula | C23H31NO4 | |
| IUPAC Name* |
(5Z)-3-[(1S,2R,4aS,6R,8aR)-6-hydroxy-1,3,6-trimethyl-2-[(E)-prop-1-enyl]-2,4a,5,7,8,8a-hexahydronaphthalene-1-carbonyl]-5-ethylidene-4-hydroxypyrrol-2-one
|
|
| SMILES |
C/C=C/[C@@H]1C(=C[C@@H]2C[C@](CC[C@H]2[C@]1(C)C(=O)C3=C(/C(=C/C)/NC3=O)O)(C)O)C
|
|
| InChI |
InChI=1S/C23H31NO4/c1-6-8-15-13(3)11-14-12-22(4,28)10-9-16(14)23(15,5)20(26)18-19(25)17(7-2)24-21(18)27/h6-8,11,14-16,25,28H,9-10,12H2,1-5H3,(H,24,27)/b8-6+,17-7-/t14-,15-,16-,22-,23-/m1/s1
|
|
| InChIKey |
KGDKEXQNSMWPCR-FBBWCXSBSA-N
|
|
| Synonyms |
Neopestalotin A
|
|
| CAS | NA | |
| PubChem CID | 139586863 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 385.5 | ALogp: | 3.0 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 86.6 | Aromatic Rings: | 3 |
| Heavy Atoms: | 28 | QED Weighted: | 0.496 |
| Caco-2 Permeability: | -5.006 | MDCK Permeability: | 0.00001980 |
| Pgp-inhibitor: | 0.02 | Pgp-substrate: | 0.187 |
| Human Intestinal Absorption (HIA): | 0.024 | 20% Bioavailability (F20%): | 0.942 |
| 30% Bioavailability (F30%): | 0.005 |
| Blood-Brain-Barrier Penetration (BBB): | 0.006 | Plasma Protein Binding (PPB): | 97.55% |
| Volume Distribution (VD): | 1.419 | Fu: | 3.82% |
| CYP1A2-inhibitor: | 0.694 | CYP1A2-substrate: | 0.704 |
| CYP2C19-inhibitor: | 0.496 | CYP2C19-substrate: | 0.273 |
| CYP2C9-inhibitor: | 0.601 | CYP2C9-substrate: | 0.936 |
| CYP2D6-inhibitor: | 0.715 | CYP2D6-substrate: | 0.342 |
| CYP3A4-inhibitor: | 0.831 | CYP3A4-substrate: | 0.325 |
| Clearance (CL): | 2.885 | Half-life (T1/2): | 0.342 |
| hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.732 |
| Drug-inuced Liver Injury (DILI): | 0.958 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.579 | Maximum Recommended Daily Dose: | 0.191 |
| Skin Sensitization: | 0.216 | Carcinogencity: | 0.027 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.038 |
| Respiratory Toxicity: | 0.937 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003602 | ![]() |
0.656 | D04GJN | ![]() |
0.277 | ||
| ENC003689 | ![]() |
0.583 | D0P0HT | ![]() |
0.256 | ||
| ENC003021 | ![]() |
0.429 | D0G8BV | ![]() |
0.252 | ||
| ENC003745 | ![]() |
0.400 | D06AEO | ![]() |
0.248 | ||
| ENC002818 | ![]() |
0.368 | D0E9KA | ![]() |
0.246 | ||
| ENC005181 | ![]() |
0.354 | D08PIQ | ![]() |
0.244 | ||
| ENC005182 | ![]() |
0.354 | D0I2SD | ![]() |
0.243 | ||
| ENC003775 | ![]() |
0.340 | D0D1SG | ![]() |
0.237 | ||
| ENC002170 | ![]() |
0.298 | D0IL7L | ![]() |
0.237 | ||
| ENC003630 | ![]() |
0.294 | D0IX6I | ![]() |
0.237 | ||